Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-14 4:17 pm Sale |
2021-12-31 | 13G | Invitae Corporation NVTAQ |
Baker Bros. Advisors LP | 9,873,488 4.400% |
-5,900,607 (-37.41%) |
Filing History |
| 2022-02-14 4:17 pm Purchase |
2021-12-31 | 13G | Rhythm Pharmaceuticals, Inc. RYTM |
Baker Bros. Advisors LP | 3,863,239 7.700% |
1,548,366 (+66.89%) |
Filing History |
| 2022-02-14 4:16 pm Purchase |
2021-12-31 | 13G | Otonomy, Inc. OTIC |
Baker Bros. Advisors LP | 7,844,692 13.800% |
624,618 (+8.65%) |
Filing History |
| 2022-02-14 4:16 pm Purchase |
2021-12-31 | 13G | Zymeworks Inc. ZYME |
Baker Bros. Advisors LP | 4,977,296 9.990% |
67,486 (+1.37%) |
Filing History |
| 2022-02-14 4:16 pm Purchase |
2021-12-31 | 13G | Mereo BioPharma Group plc MREO |
Baker Bros. Advisors LP | 64,917,601 9.990% |
25,285,672 (+63.80%) |
Filing History |
| 2022-02-14 4:16 pm Purchase |
2021-12-31 | 13G | Verastem, Inc. VSTM |
Baker Bros. Advisors LP | 1,790,969 11.800% |
233,828 (+15.02%) |
Filing History |
| 2022-02-14 4:15 pm Purchase |
2021-12-31 | 13G | Surrozen, Inc. SRZN |
Baker Bros. Advisors LP | 222,222 9.300% |
222,222 (New Position) |
Filing History |
| 2022-02-14 4:15 pm Purchase |
2021-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
Baker Bros. Advisors LP | 18,464,744 9.950% |
285,863 (+1.57%) |
Filing History |
| 2022-02-14 4:15 pm Sale |
2021-12-31 | 13G | Opthea Limited OPT |
Baker Bros. Advisors LP | 26,427,521 7.500% |
-7,535,719 (-22.19%) |
Filing History |
| 2022-02-14 4:15 pm Purchase |
2021-12-31 | 13G | Nurix Therapeutics, Inc. NRIX |
Baker Bros. Advisors LP | 2,454,082 5.500% |
2,454,082 (New Position) |
Filing History |
| 2022-02-14 4:15 pm Purchase |
2021-12-31 | 13G | Heron Therapeutics, Inc. HRTX |
Baker Bros. Advisors LP | 8,131,678 8.000% |
66,846 (+0.83%) |
Filing History |
| 2022-02-14 4:14 pm Purchase |
2021-12-31 | 13G | Immatics N.V. IMTX |
Baker Bros. Advisors LP | 4,423,731 7.000% |
4,423,731 (New Position) |
Filing History |
| 2022-02-14 4:14 pm Purchase |
2021-12-31 | 13G | Global Blood Therapeutics, Inc. GBT |
Baker Bros. Advisors LP | 3,314,765 5.100% |
3,314,765 (New Position) |
Filing History |
| 2022-02-14 4:14 pm Purchase |
2021-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE |
Baker Bros. Advisors LP | 1,831,789 7.500% |
1,831,789 (New Position) |
Filing History |
| 2022-02-14 4:13 pm Purchase |
2021-12-31 | 13G | Ascendis Pharma A/S ASND |
Baker Bros. Advisors LP | 4,541,604 8.000% |
1,001,334 (+28.28%) |
Filing History |
| 2022-02-14 4:13 pm Sale |
2021-12-31 | 13G | Amarin Corporation plc AMRN |
Baker Bros. Advisors LP | 21,293,177 5.400% |
-13,326,880 (-38.49%) |
Filing History |
| 2022-02-14 4:13 pm Purchase |
2021-12-31 | 13G | Altimmune, Inc. ALT |
Baker Bros. Advisors LP | 1,941,604 4.800% |
57,153 (+3.03%) |
Filing History |
| 2022-02-14 4:13 pm Purchase |
2021-12-31 | 13G | Aligos Therapeutics, Inc. ALGS |
Baker Bros. Advisors LP | 83,056 5.300% |
83,056 (New Position) |
Filing History |
| 2022-02-14 4:12 pm Purchase |
2021-12-31 | 13G | Achilles Therapeutics plc ACHL |
Baker Bros. Advisors LP | 4,039,480 9.990% |
4,039,480 (New Position) |
Filing History |
| 2022-02-10 5:03 pm Purchase |
2022-02-09 | 13D | Aeglea BioTherapeutics, Inc. AGLE |
Baker Bros. Advisors LP | 201,779 9.900% |
5,732 (+2.92%) |
Filing History |